[Form 4] Immunome, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Chief Legal Officer & General Counsel Sandra G. Stoneman filed an SEC Form 4 showing an option grant covering 190,000 Immunome (IMNM) shares on 07/29/2025 at a strike price of $10.60.

Vesting schedule: 25 % on 07/29/2026; the remaining 75 % vests in 36 equal monthly installments, reaching full vesting on 07/29/2029. The option expires on 07/28/2035. Transaction code “A” confirms this is an award, not an open-market trade, and no common shares were acquired or sold.

Following the grant, the reporting person holds 190,000 derivative securities and no change in direct common-share ownership. The filing represents routine, retention-focused compensation and carries minimal immediate market impact.

Insights

Securities Analyst

TL;DR: Routine option grant; neutral for valuation and insider-sentiment signals.

The 190 k option award to the CLO aligns executive incentives but does not alter Immunome’s capital structure or suggest insider conviction through share purchases. Strike price of $10.60 sits near-market, indicating standard compensation rather than deep-in-the-money motivation. Vesting over four years supports retention and long-term alignment. No non-derivative activity limits near-term dilution. Impact on shares outstanding is contingent on future exercise and therefore non-material today.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stoneman Sandra G.

(Last) (First) (Middle)

C/O IMMUNOME, INC.

18702 N. CREEK PARKWAY, SUITE 100

(Street)

BOTHELL WA 98011

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Immunome Inc. [ IMNM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF LEGAL OFFICER & GC

3. Date of Earliest Transaction (Month/Day/Year)
07/29/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$10.6	07/29/2025		A		190,000		(1)	07/28/2035	Common Stock	190,000	$0	190,000	D

Explanation of Responses:

1. 25% of the shares subject to the options vest on July 29, 2026, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter.

	/s/ Sandra Stoneman	07/31/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Immunome's (IMNM) latest Form 4 disclose?

190,000 stock options were granted to Chief Legal Officer Sandra Stoneman at a $10.60 strike price on 07/29/2025.

When do the new IMNM options vest?

25 % vest on 07/29/2026; the remaining 75 % vest monthly over the next 36 months, fully vesting by 07/29/2029.

Did the insider buy or sell any Immunome common shares?

No. The filing reports an award of derivative securities only; no common shares were purchased or sold.

How many options does the insider own after the transaction?

After the grant, Stoneman beneficially owns 190,000 stock options.

What is the expiration date of the granted IMNM options?

The options expire on 07/28/2035 if not exercised earlier.